BioNTech Faces Patent Escalation in Canada and Japan While Defending a Raised Revenue Target
Published on 11/12/2026 at 16:11 | Editorial boerse-global.de
BioNTech's week began with a legal broadside from the north. Arbutus Biopharma and Genevant Sciences moved on Tuesday to widen their Canadian patent suit against Pfizer, BioNTech and affiliated companies, folding a newly issued lipid nanoparticle (LNP) patent into the proceedings. The plaintiffs are pursuing monetary damages and court injunctions.
The same day brought parallel action in Asia. Arbutus and Genevant filed additional patent claims in Japan against Pfizer Japan, likewise seeking compensation and injunctive relief. BioNTech is named as a defendant in the expanded Canadian case, while the fresh Japanese filings target Pfizer Japan.
Those developments landed alongside a mixed third-quarter report card. BioNTech disclosed on 3 November revenue of EUR 1.29 billion for the three months to September 2026, down from EUR 1,518.9 million a year earlier. Management pinned the decline chiefly on softer expected demand for its COVID-19 vaccines. Net profit for the quarter came in at EUR 184.5 million.
Guidance Raised, Price Target Cut
Even as quarterly sales slipped, the Mainz-based company lifted the midpoint of its full-year revenue range, setting the 2026 outlook at EUR 1.7 billion to EUR 1.9 billion. Research and development spending under IFRS reached EUR 748.1 million in the third quarter alone. Across the first nine months of 2026, revenue totalled EUR 1.51 billion against R&D outlays of EUR 1.86 billion.
Should investors sell immediately? Or is it worth buying BioNTech?
The market's response was muted rather than hostile. H.C. Wainwright trimmed its price target on BioNTech to $110 from $130 on Monday, according to media reports, while keeping its buy rating intact following the quarterly update. The stock added 1.2% in the prior session.
A $205 Million Bet on Faster Review
Capital deployment did not pause for the litigation. On Tuesday, BioNTech struck an agreement with Scholar Rock to acquire a US Food and Drug Administration priority review voucher for $205 million in cash. The company intends to deploy the voucher toward a future marketing application for a late-stage oncology programme.
The transaction remains subject to customary closing conditions, including HSR clearance. Its strategic logic rests on the oncology use case: the voucher only pays off if the underlying programme advances far enough to justify a filing.
Taken together, the picture is one of a company managing a shrinking vaccine franchise while spending heavily to build a cancer pipeline — and now doing so against a widening patent fight on two continents. The raised guidance offers a marker of confidence; whether the research budget converts into durable clinical progress is the question investors will keep asking.
Ad
BioNTech Stock: New Analysis - 12 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
